english.prescrire.org > Prescrire International > N°185 - September 2017

n°185

September 2017

Issue Contents
Editorial

Free  Statins: impartial assessment

p.199

Marketing Authorisations

Nivolumab (Opdivo°) as second-line therapy for metastatic renal cell carcinoma

p.201-202
Better than everolimus

Lenvatinib (Lenvima°) in differentiated thyroid cancer

p.202-203
Uncertain harm-benefit balance

INN Common stem: -prost

p.204

Raltegravir (Isentress°) granules for infants

p.204-205
Offers an advantage

Free  Levonorgestrel for emergency contraception after an enzyme inducer: double the dose

p.205

Paliperidone (Trevicta°) for quarterly injection

p.206
Possibly helpful

Adverse Effects

Vaccination-related errors: analysing errors in order to prevent them

p.207-208

Prescrire's proposals. Preventing vaccination-related errors in practice

p.207-208

Propylene glycol: an excipient with dose-dependent adverse effects

p.209-210

Antidepressants: suicide and violence in adults with no history of mental disorders

p.211

Reviews

Statins in secondary cardiovascular prevention

p.212-220
Pravastatin is the first choice when statin therapy is justified

Table. Main randomised or quasi-randomised trials of statins in secondary cardiovascular prevention

p.214-215

Inset. Atorvastatin 80 mg: no proven mortality benefit

p.217

Prescrire's proposals. Choosing a statin for secondary cardiovascular prevention

p.220

Outlook

Free  French drug agency's recommendations on dosing devices: a step forward

p.221

Free  Healthcare for migrants: rejecting the unacceptable

p.222-223

Masthead

Free  Masthead

p.198

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe